Literature DB >> 17137090

[The cost per year of life gained: trends and internal contradictions].

Y M Smulders1, A Thijs.   

Abstract

Recently, a Dutch advisory committee to the Ministry of Health presented a report proposing criteria for health insurance coverage. A central role has been given to the criterion of cost per quality-adjusted life year (QALY) associated with medical interventions. The proposal is to limit the health-insurance coverage of such costs to 80,000 euro per QALY gained. Previously, 20,000 euro was generally considered a reasonable critical level for QALY-cost, whether for preventive or for curative interventions. Although a higher cut-off-level is now proposed by the advisory committee, recent cardiovascular prevention guidelines propose treatment criteria that are associated with much lower QALY costs, sometimes as low as 1,000 euro. With respect to financial considerations, the central role of QALY costs has been replaced in these prevention guidelines by national health budget implications. For individual patient care, these apparently opposing trends in the role and financial appreciation of QALYs have complex repercussions.

Entities:  

Mesh:

Year:  2006        PMID: 17137090

Source DB:  PubMed          Journal:  Ned Tijdschr Geneeskd        ISSN: 0028-2162


  7 in total

1.  Cost-Effectiveness of Group and Internet Cognitive Behavioral Therapy for Insomnia in Adolescents: Results from a Randomized Controlled Trial.

Authors:  Eduard J De Bruin; Francisca J A van Steensel; Anne Marie Meijer
Journal:  Sleep       Date:  2016-08-01       Impact factor: 5.849

2.  Ovarian metastases in young women with colorectal cancer: a retrospective multicenter cohort study.

Authors:  R van der Meer; C Bakkers; J A Wegdam; T Lettinga; E G Boerma; F Aarts; I H J T de Hingh; R M H Roumen
Journal:  Int J Colorectal Dis       Date:  2022-07-20       Impact factor: 2.796

3.  Prolonged conservative care versus early surgery in patients with sciatica from lumbar disc herniation: cost utility analysis alongside a randomised controlled trial.

Authors:  Wilbert B van den Hout; Wilco C Peul; Bart W Koes; Ronald Brand; Job Kievit; Ralph T W M Thomeer
Journal:  BMJ       Date:  2008-05-23

4.  Cost-Effectiveness of Cetuximab for Advanced Esophageal Squamous Cell Carcinoma.

Authors:  Vincent T Janmaat; Marco J Bruno; Suzanne Polinder; Sylvie Lorenzen; Florian Lordick; Maikel P Peppelenbosch; Manon C W Spaander
Journal:  PLoS One       Date:  2016-04-21       Impact factor: 3.240

5.  Is reduction of routine radiograph use in patients with distal radius fractures cost effective? Analysis of data from the multicentre, randomised controlled WARRIOR trial.

Authors:  Pieter van Gerven; Johanna M van Dongen; Sidney M Rubinstein; Marco F Termaat; Mostafa El Moumni; Wietse P Zuidema; Pieta Krijnen; Inger B Schipper; Maurits W van Tulder
Journal:  BMJ Open       Date:  2020-07-05       Impact factor: 2.692

6.  The cost-effectiveness of increasing alcohol taxes: a modelling study.

Authors:  Matthijs van den Berg; Pieter Hm van Baal; Luqman Tariq; Albertine J Schuit; G Ardine de Wit; Rudolf T Hoogenveen
Journal:  BMC Med       Date:  2008-11-28       Impact factor: 8.775

7.  Reduction of routine use of radiography in patients with ankle fractures leads to lower costs and has no impact on clinical outcome: an economic evaluation.

Authors:  P van Gerven; J M van Dongen; S M Rubinstein; M F Termaat; M El Moumni; W P Zuidema; P Krijnen; I B Schipper; M W van Tulder
Journal:  BMC Health Serv Res       Date:  2020-09-22       Impact factor: 2.655

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.